CRISPR Therapeutics AG CRSP shares ended the last trading session 9.2% higher at $62.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% loss over the past four weeks. This rise in share price is attributable to positive investor expectations for the company’s sole-marketed product Casgevy which received marketing approval in late 2023/early 2024. Marketed in partnership with Vertex Pharmaceuticals, Casgevy is the first FDA-approved gene therapy based on CRISPR technology. It is approved to treat two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). We expect management to start recording revenues from Casgevy sales in the second half of 2024. This company is expected to post quarterly loss of $1.37 per share in its upcoming report, which represents a year-over-year change of -39.8%. Revenues are expected to be $8.39 million, down 88% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For CRISPR Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CRSP going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> CRISPR Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Axsome Therapeutics AXSM, closed the last trading session 2.6% higher at $84.95. Over the past month, AXSM has returned 9%. Axsome's consensus EPS estimate for the upcoming report has changed -0.3% over the past month to -$1.30. Compared to the company's year-ago EPS, this represents a change of -30%. Axsome currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP):Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...